Related references
Note: Only part of the references are listed.Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update
Teresa Schaetzl et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Analysis of genes regulated by DUX4 via oxidative stress reveals potential therapeutic targets for treatment of facioscapulohumeral dystrophy
Anna Karpukhina et al.
REDOX BIOLOGY (2021)
p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets
Christopher M. Brennan et al.
JCI INSIGHT (2021)
Selective inhibitors for JNK signalling: a potential targeted therapy in cancer
Qinghua Wu et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2020)
Beyond mass spectrometry, the next step in proteomics
Winston Timp et al.
SCIENCE ADVANCES (2020)
Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity
Takako I. Jones et al.
SKELETAL MUSCLE (2020)
p38 alpha Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy
L. Alejandro Rojas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
MSstatsTMT: Statistical Detection of Differentially Abundant Proteins in Experiments with Isobaric Labeling and Multiple Mixtures
Ting Huang et al.
MOLECULAR & CELLULAR PROTEOMICS (2020)
JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia
Scott E. Mulder et al.
CANCER LETTERS (2020)
Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy
Jonathan Oliva et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy
Sujatha Jagannathan et al.
ELIFE (2019)
Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle
Amy E. Campbell et al.
HUMAN MOLECULAR GENETICS (2018)
A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy
Takako Jones et al.
PLOS ONE (2018)
JNK regulates muscle remodeling via myostatin/SMAD inhibition
Sarah J. Lessard et al.
NATURE COMMUNICATIONS (2018)
DUX-family transcription factors regulate zygotic genome activation in placental mammals
Alberto De Iaco et al.
NATURE GENETICS (2017)
Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons
Peter G. Hendrickson et al.
NATURE GENETICS (2017)
Salmon provides fast and bias-aware quantification of transcript expression
Rob Patro et al.
NATURE METHODS (2017)
Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model
Darko Bosnakovski et al.
NATURE COMMUNICATIONS (2017)
DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy
Sean C. Shadle et al.
PLOS GENETICS (2017)
ROBUST HYPERPARAMETER ESTIMATION PROTECTS AGAINST HYPERVARIABLE GENES AND IMPROVES POWER TO DETECT DIFFERENTIAL EXPRESSION
Belinda Phipson et al.
ANNALS OF APPLIED STATISTICS (2016)
DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients
Petr Dmitriev et al.
FREE RADICAL BIOLOGY AND MEDICINE (2016)
Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells
Sujatha Jagannathan et al.
HUMAN MOLECULAR GENETICS (2016)
A new view of transcriptome complexity and regulation through the lens of local splicing variations
Jorge Vaquero-Garcia et al.
ELIFE (2016)
Influence of Repressive Histone and DNA Methylation upon D4Z4 Transcription in Non-Myogenic Cells
Sunny Das et al.
PLOS ONE (2016)
Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways
Amanda M. Rickard et al.
HUMAN MOLECULAR GENETICS (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
Qing Feng et al.
ELIFE (2015)
Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation
Sachiko Homma et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Recent Progress in the Design, Study, and Development of c-Jun N-Terminal Kinase Inhibitors as Anticancer Agents
Abdellah Messoussi et al.
CHEMISTRY & BIOLOGY (2014)
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Charity W. Law et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Measuring and Managing Ratio Compression for Accurate iTRAQ/TMT Quantification
Mikhail M. Savitski et al.
JOURNAL OF PROTEOME RESEARCH (2013)
DUX4 Binding to Retroelements Creates Promoters That Are Active in FSHD Muscle and Testis
Janet M. Young et al.
PLOS GENETICS (2013)
DUX4 Activates Germ line Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy
Linda N. Geng et al.
DEVELOPMENTAL CELL (2012)
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2
Richard J. L. F. Lemmers et al.
NATURE GENETICS (2012)
MAP Kinase Pathways
Deborah K. Morrison
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
DUX4, a Candidate Gene for Facioscapulohumeral Muscular Dystrophy, Causes p53-Dependent Myopathy In Vivo
Lindsay M. Wallace et al.
ANNALS OF NEUROLOGY (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Mechanisms and functions of p38 MAPK signalling
Ana Cuadrado et al.
BIOCHEMICAL JOURNAL (2010)
A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy
Richard J. L. F. Lemmers et al.
SCIENCE (2010)
Facioscapulohumeral Dystrophy: Incomplete Suppression of a Retrotransposed Gene
Lauren Snider et al.
PLOS GENETICS (2010)
Differential expression analysis for sequence count data
Simon Anders et al.
GENOME BIOLOGY (2010)
The SR protein family of splicing factors: master regulators of gene expression
Jennifer C. Long et al.
BIOCHEMICAL JOURNAL (2009)
Common Epigenetic Changes of D4Z4 in Contraction-Dependent and Contraction-Independent FSHD
Jessica C. de Greef et al.
HUMAN MUTATION (2009)
JNK signaling in apoptosis
D. N. Dhanasekaran et al.
ONCOGENE (2008)
Semi-supervised learning for peptide identification from shotgun proteomics datasets
Lukas Kall et al.
NATURE METHODS (2007)
The c-jun kinase/stress-activated pathway: Regulation, function and role in human disease
Gary L. Johnson et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
P38 MAP-Kinases pathway regulation, function and role in human diseases
Ana Cuenda et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Role of mitogen-activated protein kinase kinase kinases in signal integration
B. D. Cuevas et al.
ONCOGENE (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope
JL Perfettini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation
EH Goldman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential
MA Bogoyevitch et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
Mechanism of p38 MAP kinase activation in vivo
D Brancho et al.
GENES & DEVELOPMENT (2003)
Targeting JNK for therapeutic benefit: From JuNK to gold?
AM Manning et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
BL Bennett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis
K Tobiume et al.
EMBO REPORTS (2001)
JNK is required for effector T-cell function but not for T-cell activation
C Dong et al.
NATURE (2000)
Share Paper
